On June 11, Arterial Network learned that Baiyang Intelligent Technology and Medical Branch of Baiyang Pharmaceutical Group jointly announced that they have signed a strategic cooperation agreement with Watson for Oncology (WfO) to jointly promote the application of medical artificial intelligence in the field of cancer therapy. Patients provide personalized, standardized treatment options.
Bai Gang, chairman of Baiyang Pharmaceutical Group, said that Baiyang Pharmaceutical Group's large tumor strategy hopes to provide a total solution for cancer patients at different stages, so that the scene of tumor treatment is more and more perfect and mature. This can't be done by a company. From Asia, Oracle, Philips, to Medical Science, Baiyang is looking for the best companies in the industry to cooperate and build a better solution.
Domestic radiotherapy accounted for a low proportion, introducing mature medical AI products to make up the gap
Among the three major treatments for tumors, treatment methods can be initially classified into surgical treatment, radiation therapy, and chemotherapy.
According to WHO data, about 70% of cancer patients need radiation therapy in the treatment of cancer, and about 40% of cancers can be cured by radiotherapy. The role and status of radiotherapy in the treatment of cancer has become increasingly prominent and has become one of the main methods for the treatment of malignant tumors.
There were 4292,000 new cases of tumors in China in 2015, and 3004400 new cases of tumors requiring radiotherapy in 2015. According to the 2015 Basic Survey of Radiotherapy in Mainland China, 919,339 patients received radiotherapy in 2015. Accounted for 30.5% of new-onset patients requiring radiotherapy.
Source: National Cancer Center, California Cancer Registry, Literature Search
Compared with developed countries such as the United States, China's cancer treatment methods are characterized by high drug proportion, low operation rate and low radiation rate. According to data from 2015, the proportion of cancer therapeutics in China is much higher than that in the United States, while the proportion of radiotherapy in the United States far exceeds that in China. At least 65%-80% of patients in the United States use radiotherapy during treatment, compared with 30% in China.
The proportion of radiotherapy is low. On the one hand, the number of accelerators per million people in China is only 1.49, which is still different from the 2 to 3 accelerators per million people required by the WHO. The bottleneck of tumor radiotherapy also includes the shortage of professional medical technicians and the relative lag of treatment technology. The systematic, standardization and process of radiation oncology need to be strengthened.
As far as radiotherapy itself is concerned, there is a large individual difference in the sensitivity of patients with malignant tumors to radiotherapy. In many cases, the standard radiotherapy dose given to patients may be over-treated for some patients, and some patients may have insufficient treatment intensity. . The introduction of WfO, an advanced artificial intelligence solution in the global medical field, is an important basis for achieving accurate and personalized radiotherapy for cancer patients.
AI empowers tumor radiation therapy to enhance doctor confidence
Fu Gang said: "Artificial intelligence is only a component, and it can be integrated into various medical scenarios to form a whole solution to release value. WfO shows in the scenes of radiotherapy time management, MDT consultation communication, round room doctor training and patient second diagnosis opinion. The value of the optimization and efficiency enhancement is obvious. Therefore, we are honored to cooperate with the medical science to integrate the world's top medical artificial intelligence product WfO into the tumor radiotherapy, help Chinese doctors to provide patients with more appropriate treatment plans and promote together. China's medical care is developing in an all-round way toward precision and intelligence."
The lack of professional medical technicians and the relative lag of treatment techniques are an important reason for the low proportion of radiotherapy.
In 2015, there were a total of 50,736 people undergoing radiotherapy in the country. Among them, physicians (including general hospital oncologists), physicists, nurses, and technicians were 15,841, 3,294, 23,152, and 8454, respectively. Compared with the number of radiotherapy practitioners in 2011, the number of employees increased. 63.74%. However, the proportion of radiotherapy physicians and physicists is only 4.81:1. In developed countries and regions such as the United States, the ratio of radiotherapy physicians to physicists is about 1:1, and there is still a big gap. The relationship between the radiologist and the physicist is like the relationship between the surgeon and the anesthesiologist. Good anesthesia is the prerequisite for the smooth implementation of surgery, and physics is the guarantee for the smooth implementation of radiotherapy. Both of them perform their duties, but they complement each other and are indispensable.
In the short term, the number of doctors and technicians will be increased to increase the number of radiotherapy in China. The difficulty is very large. However, it is achievable to use artificial intelligence technology to assist doctors in quality control and to enhance the confidence of masses of radiologists and technicians.
In fact, WfO has stored and studied a large number of MSKCC tumor cases, more than 300 medical journals, more than 250 tumor monographs, and more than 15 million paper research data, as well as NCCN-based cancer treatment guidelines and MSKCC multi-year cancer clinical treatment practices. Experience and so on. Currently covering 13 kinds of tumors, compared with the treatment plan given by the top expert group, the treatment plan of WfO has reached more than 90% compliance, and has gradually become an important intelligent assistant for oncologists, and has 39 in 22 provinces in China. The city's 68 medical institutions have landed, providing a standardized and personalized treatment plan for nearly 20,000 cancer patients.
Elekta is a pioneer in radiation therapy and neuroscience solutions, including world-class linear accelerators, specialized radiosurgery equipment, brachytherapy systems, oncology information management systems, and treatment planning software solutions. To date, Elekta's solutions for oncology, neurosurgery, and oncology information management software have been used in more than 6,000 hospitals around the world to provide diagnostic and therapeutic services to more than 100,000 patients every day. MOSAIQ® is the leading digital platform at home and abroad, integrating the digital devices, clinical processes and healthcare resources of modern radiotherapy centers. This platform provides high-quality data for clinical research, deep learning and artificial intelligence.
Radiotherapy is a complex project that includes radiotherapy plan development, discharge plan review, and radiotherapy plan implementation. In the process, it will generate a huge amount of data, involving doctors, technicians, nurses, and many other medical personnel. Will affect the effect of radiotherapy. The cooperation between Baiyang and Medical Science will provide services to medical staff throughout the radiotherapy process and enhance their confidence.
But Fu Gang also stressed that Baiyang's cooperation with a professional company like Medical Star is because of mature AI products like WfO, WfG (Watson for Genomics), it is only a component. Just like a car, what we need is a car that can run, not an engine. For a single component, it can't save the patient. It can only be integrated into the medical scene, combined with a variety of other components and services, can really save the patient under the control of the doctor.
Watson sales are expected to exceed 500 million
Based on a more precise and personalized evidence-based diagnosis and treatment of cancer, the first phase of the cooperation between Baiyang and Medical will focus on how to maximize the advantages of WfO in intelligent decision-making for precise tumor radiotherapy.
In this regard, Gong Anming, the global executive vice president of China Medical Group and the president of China, said, “I am very pleased to be able to cooperate with Baiyang Intelligent Technology to introduce and develop the application of artificial intelligence WfO in the Chinese market, especially to provide individuality for cancer radiotherapy. The treatment plan will further enhance our comprehensive strength in the field of cancer radiotherapy, so as to bring intelligent treatment solutions to more Chinese users. I believe that the cooperation between the two sides will fully promote the direction of precision, personalization and intelligence of Chinese medical care. The development will benefit more Chinese cancer patients."
Talking about the mode of cooperation, Fugang said that the cooperation between the two sides will gradually deepen. The first stage is that Medical Branch purchases Baiyang's WfO and becomes a distributor of Baiyang, providing products to doctors so that doctors can more accurately judge the treatment of radiotherapy. Time and radiotherapy options. In the longer run, Baiyang and Elekta will cooperate more deeply and buy each other's products. Baiyang advocates an ecological cooperation, strong alliance, and mutual complementation of ecological resources.
As the leader of China's new medical informationization , Baiyang Intelligent Technology is committed to science and technology to improve health, and is the first to realize software SaaS, mobile HIS, and decision-making intelligence. In particular, in promoting the rapid layout of Watson's tumors, the company is committed to localizing China's national conditions, making products more suitable for Chinese patients and doctors to use, to provide personalized diagnosis and treatment services for patients. It is estimated that by the end of this year, Watson tumors will cover nearly 100 dealers nationwide, and overall sales are expected to exceed 500 million.
We're Professional Supplier Extract Powder manufacturers and suppliers in China specialized in providing high-quality products at low price. We warmly welcome you to buy or wholesale bulk Supplier Extract Powder for sale here from our factory. For a free sample, contact us now.
Supplier Extract Powder,Supplier Extract ,Supplier Powder Manufacturer in China
Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.kangnewpharmas.com